Leslie Matalonga

Leslie Matalonga

Auto-generated profile, based on publicly available information

Leslie Matalonga

Centro Nacional de Análisis Genómico (CNAG), Barcelona, Spain

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2013 in Human Molecular Genetics
Verified
Journal Article
Open access
FTFrederic Tort
Frederic Tort
XFXènia Ferrer-Cortès
Xènia Ferrer-Cortès
MTMarta Thió
Marta Thió
ANAleix Navarro-Sastre
Aleix Navarro-Sastre
LMLeslie Matalonga
Leslie Matalonga
ARAntonia Ribes
Antonia Ribes
Cofactor disorders of mitochondrial energy metabolism are a heterogeneous group of diseases with a wide variety of clinical symptoms, particular metabolic profiles and variable enzymatic defects. Mutations in NFU1, BOLA3, LIAS and IBA57 have been identified in patients with deficient lipoic acid-dependent enzymatic activities and defects in the assembly and activity of the mitochondrial respiratory chain complexes. Here, we report a patient with an early onset fatal lactic acidosis presenting a biochemical phenotype compatible with a combined defect of pyruvate dehydrogenase (PDHC) and 2-ketoglutarate dehydrogenase (2-KGDH) activities, which suggested a deficiency in lipoic acid metabolism. Immunostaining analysis showed that lipoylated E2-PDH and E2-KGDH were extremely reduced in this patient. However, the absence of glycine elevation, the normal activity of the glycine cleavage system and the normal lipoylation of the H protein suggested a defect of lipoic acid transfer to particular proteins rather than a general impairment of lipoic acid biosynthesis as the potential cause of the disease. By analogy with yeast metabolism, we postulated LIPT1 as the altered candidate gene causing the disease. Sequence analysis of the human LIPT1 identified two heterozygous missense mutations (c.212C>T and c.292C>G), segregating in different alleles. Functional complementation experiments in patient's fibroblasts demonstrated that these mutations are disease-causing and that LIPT1 protein is required for lipoylation and activation of 2-ketoacid dehydrogenases in humans. These findings expand the spectrum of genetic defects associated with lipoic acid metabolism and provide the first evidence of a lipoic acid transfer defect in humans.

31 October 2012 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
GTGustavo Tiscornia
Gustavo Tiscornia
EVErika Lorenzo Vivas
Erika Lorenzo Vivas
LMLeslie Matalonga
Leslie Matalonga
IBIna Berniakovich
Ina Berniakovich
MMMontserrat Barragán Monasterio
Montserrat Barragán Monasterio
Juan Carlos Izpisua BelmonteJuan Carlos Izpisua Belmonte
Juan Carlos Izpisua Belmonte
Gaucher's disease (GD) is caused by mutations in the GBA1 gene, which encodes acid-β-glucosidase, an enzyme involved in the degradation of complex sphingolipids. While the non-neuronopathic aspects of the disease can be treated with enzyme replacement therapy (ERT), the early-onset neuronopathic form currently lacks therapeutic options and is lethal. We have developed an induced pluripotent stem cell (iPSc) model of neuronopathic GD. Dermal fibroblasts of a patient with a P.[LEU444PRO];[GLY202ARG] genotype were transfected with a loxP-flanked polycistronic reprogramming cassette consisting of Oct4, Sox2, Klf4 and c-Myc and iPSc lines derived. A non-integrative lentiviral vector expressing Cre recombinase was used to eliminate the reprogramming cassette from the reprogrammed cells. Our GD iPSc express pluripotent markers, differentiate into the three germ layers, form teratomas, have a normal karyotype and show the same mutations and low acid-β-glucosidase activity as the original fibroblasts they were derived from. We have differentiated them efficiently into neurons and also into macrophages without observing deleterious effects of the mutations on the differentiation process. Using our system as a platform to test chemical compounds capable of increasing acid-β-glucosidase activity, we confirm that two nojirimycin analogues can rescue protein levels and enzyme activity in the cells affected by the disease.

20 May 2022 in Human Mutation
Verified
Journal Article
Open access
PDF file
SLSteven Laurie
Steven Laurie
DPDavide Piscia
Davide Piscia
LMLeslie Matalonga
Leslie Matalonga
ACAlberto Corvo
Alberto Corvo
CGCarles Garcia
Carles Garcia
SBSergi Beltran
Sergi Beltran
Rare disease patients are more likely to receive a rapid molecular diagnosis nowadays thanks to the wide adoption of next generation sequencing. However, many cases remain undiagnosed even after exome or genome analysis, because the methods used missed the molecular cause in a known gene, or a novel causative gene could not be identified and/or confirmed. To address these challenges, the RD-Connect Genome-Phenome Analysis Platform (GPAP) facilitates the collation, discovery, sharing and analysis of standardised genome-phenome data within a collaborative environment. Authorised clinicians and researchers submit pseudonymised phenotypic profiles encoded using the Human Phenotype Ontology, and raw genomic data which is processed through a standardised pipeline. After an optional embargo period, the data is shared with other platform users, with the objective that similar cases in the system and queries from peers may help diagnose the case. Additionally, the platform enables bidirectional discovery of similar cases in other databases from the Matchmaker Exchange network. To facilitate genome-phenome analysis and interpretation by clinical researchers, the RD-Connect GPAP provides a powerful user-friendly interface and leverages tens of information sources. As a result, the resource has already helped diagnose hundreds of rare disease patients and discover new disease causing genes.

26 November 2016 in Human Mutation
Verified
Journal Article
Closed access
PDF file
LMLeslie Matalonga
Leslie Matalonga
MBMiren Bravo
Miren Bravo
CSCarla Serra-Peinado
Carla Serra-Peinado
EGElisabeth García-Pelegrí
Elisabeth García-Pelegrí
OUOlatz Ugarteburu
Olatz Ugarteburu
MGMarisa Girós
Marisa Girós

12 August 2020 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
AAAntonio Atalaia
Antonio Atalaia
RTRachel Thompson
Rachel Thompson
ACAlberto Corvo
Alberto Corvo
LCLeigh Carmody
Leigh Carmody
DPDavide Piscia
Davide Piscia
GBGisèle Bonne
Gisèle Bonne
Background: Rare diseases are individually rare but globally affect around 6% of the population, and in over 70% of cases are genetically determined. Their rarity translates into a delayed diagnosis, with 25% of patients waiting 5 to 30 years for one. It is essential to raise awareness of patients and clinicians of existing gene and variant-specific therapeutics at the time of diagnosis to avoid that treatment delays add up to the diagnostic odyssey of rare diseases’ patients and their families. Aims: This paper aims to provide guidance and give detailed instructions on how to write homogeneous systematic reviews of rare diseases’ treatments in a manner that allows the capture of the results in a computer-accessible form. The published results need to comply with the FAIR guiding principles for scientific data management and stewardship to facilitate the extraction of datasets that are easily transposable into machine-actionable information. The ultimate purpose is the creation of a database of rare disease treatments (“Treatabolome”) at gene and variant levels as part of the H2020 research project Solve-RD. Results: Each systematic review follows a written protocol to address one or more rare diseases in which the authors are experts. The bibliographic search strategy requires detailed documentation to allow its replication. Data capture forms should be built to facilitate the filling of a data capture spreadsheet and to record the application of the inclusion and exclusion criteria to each search result. A PRISMA flowchart is required to provide an overview of the processes of search and selection of papers. A separate table condenses the data collected during the Systematic Review, appraised according to their level of evidence. Conclusions: This paper provides a template that includes the instructions for writing FAIR-compliant systematic reviews of rare diseases’ treatments that enables the assembly of a Treatabolome database that complement existing diagnostic and management support tools with treatment awareness data.

22 November 2012 in Journal of Inherited Metabolic Disease
Verified
Journal Article
Closed access
PDF file
XFXènia Ferrer‐Cortès
Xènia Ferrer‐Cortès
AFAida Font
Aida Font
NBNúria Bujan
Núria Bujan
ANAleix Navarro‐Sastre
Aleix Navarro‐Sastre
LMLeslie Matalonga
Leslie Matalonga
FTFrederic Tort
Frederic Tort